Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 7 Feb 2025 |
| Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons | 6 Feb 2025 |
| Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024 | 5 Feb 2025 |
| Novo Nordisk A/S - share repurchase programme | 4 Feb 2025 |
| Novo Nordisk A/S - share repurchase programme | 27 Jan 2025 |
| Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity | 24 Jan 2025 |